Award

ERA-NET NEURON: The Gut Microbiome in Neuroinflammation and Neurodevelopmental Disorders

Description: The brain is an extraordinarily complex organ that develops early on in embryonic life. Neurodevelopment results from the execution of epigenetic and genetic programs, and is strongly influenced by environmental factors. A precise sequence of events is initiated, hich, while disrupted by genetic defects or environmental insults such as infections, provokes non-recoverable developmental alterations leading to mental diseases. In addition to the synaptic and/or connectivity dysfunctions associated to neurodevelopmental disorders, inflammation in the brain (otherwise called neuroinflammation) is one of the hallmarks shared by different neurodevelopmental disorders, such as Down syndrome, Fragile X syndrome and Autism Spectrum Disorders. In fact, neuroinflammation drastically affects brain activity and behaviour. Recent studies demonstrate the existence of a gutbrain axis through which the intestinal microbiota is able to modulate inflammation and impact behaviour. The µNeuroINF project will explore the hypothesis that our gut bacteria may trigger neuroinflammation, which in turn impacts metabolism and behaviour, and ultimately contributes to neurodevelopmental disease progression. Using mouse models of Down syndrome, Fragile X syndrome and autism spectrum disorders, we will study the gut bacteria, their genes, proteins and metabolites to identify which microbial metabolites common to these diseases are absorbed in the gut and diffuse into the bloodstream to reach the brain. The potential pro-inflammatory role of these metabolites will be investigated in vitro by screening their pharmacological targets in the host, and in vivo in the animal models of the disease. This will ultimately lead to novel therapeutic strategies for NDD driven by the gut microbiome. The µNeuroINF initiative is an innovative multidisciplinary project targeting the role of the gut bacteria in neuroinflammation. Our unique research strategy uses cuttingedge technologies to explore how gut microbes modulate brain inflammation in neurodevelopmental disorders. Not only the project will demonstrate one of the most fundamental mechanisms by which our gut bacteria influence our behaviour, but it will also identify the microbial metabolites that can be used to better monitor brain inflammation ("biomarkers") or to lead to new drugs ("lead compounds") for the treatment of neuroinflammation
Amount: £348,700
Funding type: research
Start date: 2015-04-19
End date: 2018-09-17
Funded outputs count: 25
Funder award ID: MR/M501797/1
OpenAlex ID: G6184027149
2026 · Toby Lawrence, Ema Mocsonokyova, et al. · Briefings in Bioinformatics · 1
2023 · Sergio Quesada-Vázquez, Anna Castells-Nobau, et al. · Cell Reports Medicine · 55
2022 · Elisabeth Serger, Lucia Luengo-Gutierrez, et al. · Nature · 384
2021 · Patricia Bermudez-Martin, Jérôme A. J. Becker, et al. · Microbiome · 166
2021 · Jordi Mayneris-Perxachs, Marina Cardellini, et al. · Microbiome · 142
2020 · P. Bermudez-Martin, J. A. J. Becker, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 10
2020 · Francois Brial, Fawaz Alzaid, et al. · Cell Reports · 59
2019 · Ana Luisa Neves, Andrea Rodriguez-Martinez, et al. · bioRxiv (Cold Spring Harbor Laboratory)
2019 · Mohd Badrin Hanizam Abdul Rahim, Julien Chilloux, et al. · Acta Diabetologica · 127
2019 · Antoine Leboucher, Didier F. Pisani, et al. · Molecular Metabolism · 58
2018 · Lesley Hoyles, José-Manuel Fernández-Real, et al. · Nature Medicine · 19
2018 · Lesley Hoyles, José-Manuel Fernández-Real, et al. · Nature Medicine · 734
2016 · Julien Chilloux, Ana Luisa Neves, et al. · Current Opinion in Clinical Nutrition & Metabolic Care · 28
2016 · Claire L. Boulangé, Ana Luisa Neves, et al. · Genome Medicine · 1,485
2016 · Marc-Emmanuel Dumas · Genome Medicine · 4
2015 · Ana Luisa Neves, Julien Chilloux, et al. · Current Opinion in Pharmacology · 36
2015 · Marc-Emmanuel Dumas, Laetitia Davidovic · Journal of Neuroimmune Pharmacology · 49
Year
Topic